首页> 美国卫生研究院文献>Antibodies >Host Cell Proteins in Biologics Manufacturing: The Good the Bad and the Ugly
【2h】

Host Cell Proteins in Biologics Manufacturing: The Good the Bad and the Ugly

机译:生物制剂制造中的宿主细胞蛋白质:好坏和丑陋

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Significant progress in the manufacturing of biopharmaceuticals has been made by increasing the overall titers in the USP (upstream processing) titers without raising the cost of the USP. In addition, the development of platform processes led to a higher process robustness. Despite or even due to those achievements, novel challenges are in sight. The higher upstream titers created more complex impurity profiles, both in mass and composition, demanding higher separation capacities and selectivity in downstream processing (DSP). This creates a major shift of costs from USP to DSP. In order to solve this issue, USP and DSP integration approaches can be developed and used for overall process optimization. This study focuses on the characterization and classification of host cell proteins (HCPs) in each unit operation of the DSP (i.e., aqueous two-phase extraction, integrated countercurrent chromatography). The results create a data-driven feedback to the USP, which will serve for media and process optimizations in order to reduce, or even eliminate nascent critical HCPs. This will improve separation efficiency and may lead to a quantitative process understanding. Different HCP species were classified by stringent criteria with regard to DSP separation parameters into “The Good, the Bad, and the Ugly” in terms of pI and MW using 2D-PAGE analysis depending on their positions on the gels. Those spots were identified using LC-MS/MS analysis. HCPs, which are especially difficult to remove and persistent throughout the DSP (i.e., “Bad” or “Ugly”), have to be evaluated by their ability to be separated. In this approach, HCPs, considered “Ugly,” represent proteins with a MW larger than 15 kDa and a pI between 7.30 and 9.30. “Bad” HCPs can likewise be classified using MW (>15 kDa) and pI (4.75–7.30 and 9.30–10.00). HCPs with a MW smaller than 15 kDa and a pI lower than 4.75 and higher than 10.00 are classified as “Good” since their physicochemical properties differ significantly from the product. In order to evaluate this classification scheme, it is of utmost importance to use orthogonal analytical methods such as IEX, HIC, and SEC.
机译:通过增加USP(上游加工)效价的总体效价而不增加USP的成本,在生物制药的生产上已取得重大进展。此外,平台流程的发展带来了更高的流程稳健性。尽管取得了这些成就,但还是面临着新的挑战。较高的上游滴定度会在质量和组成上造成更复杂的杂质分布,要求在下游处理(DSP)中具有更高的分离能力和选择性。这导致成本从USP到DSP的重大转变。为了解决此问题,可以开发USP和DSP集成方法并将其用于总体过程优化。这项研究的重点是DSP的每个单元操作中宿主细胞蛋白(HCP)的表征和分类(即水相两相萃取,集成逆流色谱法)。结果为USP创建了数据驱动的反馈,该反馈将用于优化媒体和流程,以减少甚至消除新生的关键HCP。这将提高分离效率,并可能导致对定量过程的理解。根据2D-PAGE分析,根据DSP分离参数的严格要求,将不同的HCP种类根据pI和MW按照DSP分离参数分为“好,坏和丑”。使用LC-MS / MS分析鉴定出这些斑点。 HCP尤其难以删除,并且在整个DSP中始终存在(即“不良”或“丑陋”),因此必须根据其分离能力进行评估。在这种方法中,被认为是“丑陋”的HCP代表了分子量大于15 kDa且pI在7.30和9.30之间的蛋白质。同样,可以使用MW(> 15 kDa)和pI(4.75-7.30和9.30-10.00)对“不良” HCP进行分类。分子量小于15 kDa且pI低于4.75且高于10.00的HCP被归类为“良好”,因为它们的理化性质与产品明显不同。为了评估此分类方案,使用正交分析方法(例如IEX,HIC和SEC)至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号